Texas Biomedical Research Institute 2021 Financial Report

2021 Financial Report

2021 FINANCIAL REPORT

WELCOME TO TEXAS BIOMED’S

2021 FINANCIAL REPORT

A

s a nonprofit research institute, Texas Biomed is committed to sharing its financial health with its donors, partners and community members. The annual financial report provides an overview of income streams, which include grants from federal agencies such as the National Institutes of Health (NIH) and Department of Defense; contracts with industry partners, such as Regeneron; philanthropic grants from individuals and organizations; and the Texas Biomed endowment originally seeded by founder Tom Slick, Jr.

underwriting the bonds, with support from many other partners. As part of the process, Texas Biomed had its credit worthiness evaluated for the first time in its 80-year history.

The Institute received an investment grade credit rating of Baa1 Bruce Edwards from Moody’s. Still, Executive Vice President and Chief Financial Officer Edwards was not sure how interested investors would be in Texas Biomed bonds as a new investment option.

This is followed by a detailed list of grants and contracts, many of which are secured through the tireless efforts of Texas Biomed scientists writing and submitting grant applications. The Institute’s Sponsored Programs Administration team also plays an essential role, working with scientists from beginning to end on project funding, including helping to ensure regulatory compliance once awards are received.

“Ultimately, we had more buyers than bonds available,” Edwards says.

The bond sale was so successful, it was named the 2021 Deal of the Year by Smith’s Research and Gradings, an investment research and analysis company. Smith’s annual Municipal All-Star Awards recognize outstanding municipal bond analysts and investments, based on votes by 1,000 institutional investors.

Edwards and his partners accepted the award at a ceremony in New York City in December 2021.

In 2021, under the leadership of Executive Vice President and Chief Financial Officer Bruce Edwards, Texas Biomed added a new source of infrastructure project funding to its portfolio: municipal bonds. In September 2021, Texas Biomed sold $65 million in municipal bonds.

The bond sale helped retire $43 million in shortterm bank loans that funded new laboratories and campus upgrades over the past five years.

It also raised $22 million in new capital, which will support ongoing efforts to expand Texas Biomed’s infectious disease research capabilities as part of its 10-year strategic plan.

“Out of all the municipal bond transactions in a given year, the analysts picked our inaugural bond offering as the deal of the year,” Edwards says. “That’s incredible recognition from the Wall Street community, further validating we are on the right track with our strategic plan and ensuring steady financial footing into the future.”

Edwards worked with Bank of America and Siebert Williams Shank & Co., LLC on 2

FINANCIALS

2021 REVENUE BASED ON 2021 AUDITED REPORT

42.0% Federal Grants 1.6% Non-Federal Grants 20.7% Federal Contracts

7.0% Commercial Contracts 0.3% Non-Federal Contracts 6.6% Restricted Contributions 7.0% Unrestricted Contributions 12.7% Investment Income 1.3% Royalty Income 0.4% External Program Income 0.4% Other Income

2021 VALUE OF ENDOWMENT IN MILLIONS OF DOLLARS

$130

$125.1 $117.4 $118.3

$120

$111.5

$114.7 $113.9 $116.3

$114.6 $107.2

$100.8

$100 $91.4 $80

$60

2011

2012

2013

2014

2015

2016

3

2017

2018

2019

2020

2021

RESEARCH GRANTS & CONTRACTS AWARDED IN 2021 INDUSTRY GRANTS & CONTRACTS SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

ARROWHEAD PHARMACEUTICALS, INC. SARS-CoV-2 siRNA testing in VeroE6 cells

Viraj Kulkarni

CONSTANT THERAPEUTICS, LLC Development of novel host response therapies to mitigate tissue damage in viral infections

Brandon Henry

JANSSEN PHARMACEUTICALS, INC. Screen NHP samples in ZEBOV and EBOV ELISA

Cory Hallam

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA Evaluate in vivo cytotoxicity and anti-SARS-CoV-2 efficacy of PCCA compound in mouse model of SARS-CoV-2

Varun Dwivedi

TONIX PHARMACEUTICALS In vitro SARS-CoV-2 infection and RNA isolation after TNX3500 treatment

Viraj Kulkarni

VIR BIOTECHNOLOGY, INC. Determine therapeutic efficacy of “Research Compound” against murine model of M.tb

Varun Dwivedi

INDUSTRY SUBTOTAL: $8,613,818 * * Subtotal includes contracts under non-disclosure agreements

PHILANTHROPIC GRANTS SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

ANIMAL WELFARE INSTITUTE Behavioral and physiological effects of implementing visual barriers in marmoset housing

Corinna Ross

BILL & MELINDA GATES FOUNDATION Testing mAbs against SARS-CoV-2 using rodent model

Jordi B. Torrelles

COWLES MEMORIAL TRUST The transcriptional signature of competition and cooperation in malaria infections

Kate Vendreley

COWLES MEMORIAL TRUST A host and viral targeted combinatory therapy for treating influenza

Brandon Henry

DOUGLASS FOUNDATION Characterizing rSARS-CoV-2 reporter genes to overcome current limitations

Kevin Chiem

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH / UT HEALTH SAN ANTONIO San Antonio Ligand Consortium

Marcel Daadi

SAN ANTONIO MEDICAL FOUNDATION Type I interferon and severe COVID-19 outcomes in humans and nonhuman primates

Dhiraj Singh

SAN ANTONIO MEDICAL FOUNDATION / UT HEALTH SAN ANTONIO Repurposing drugs for COVID-19 therapy

Luis Martinez-Sobrido

SAN ANTONIO MEDICAL FOUNDATION / UT HEALTH SAN ANTONIO Calming the cytokine storm with proteasome-targeting immunomodulators

Larry Schlesinger

TEXAS BIOMEDICAL FORUM The impact of zinc transporter ZIP8 during M.tb macrophage infection

Eusondia Arnett

TEXAS BIOMEDICAL FORUM Deciphering the impact of the lung microenvironment on alveolar macrophage recruitment and function in old age Susanta Pahari 4

SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

TEXAS BIOMEDICAL FORUM Molecular probes specific for surface antigens of brain eating amoeba Naegleria fowleri

Andrew Hayhurst

TEXAS BIOMEDICAL FORUM Autologous mitochondrial transplantation

Jordi B. Torrelles

TEXAS BIOMEDICAL FORUM Deciphering early M.tb and host determinants driving infection outcomes

Anna Allué Guardia

PHILANTHROPIC SUBTOTAL: $1,402,166

NON-FEDERAL GRANTS & CONTRACTS SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

AMERICAN COLLEGE OF LABORATORY ANIMAL MEDICINE Compare sedative, anesthetic and cardiopulmonary effects of telazol in common marmosets

Anna Goodroe

CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER Study M.tb disease progression in LDH deficient mice

Varun Dwivedi

SAN ANTONIO PARTNERSHIP FOR PRECISION THERAPEUTICS CRISPR-based RNA targeting for HIV intervention

Smita Kulkarni

SAN ANTONIO PARTNERSHIP FOR PRECISION THERAPEUTICS / SOUTHWEST RESEARCH INSTITUTE Develop antiviral therapies against Nipah and Hendra viruses

Olena Shtanko

SAN ANTONIO PARTNERSHIP FOR PRECISION THERAPEUTICS / UT HEALTH SAN ANTONIO Electronic health record big data and radiomic analytics

Diako Ebrahimi

SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER Behavioral and physiological effects of implementing visual barriers in marmoset housing

Corinna Ross

UT HEALTH SAN ANTONIO Graduate student research funding

Larry Schlesinger

UT HEALTH SAN ANTONIO Therapeutic application of antidepressants in COVID-19: mitigating the cytokine storm

Luis Martinez-Sobrido

NON-FEDERAL SUBTOTAL: $242,715

FEDERAL GRANTS & CONTRACTS SPONSOR, MECHANISM & TITLE

PRINCIPAL INVESTIGATOR

NATIONAL INSTITUTES OF HEALTH (NIH) RO1 Genomic consequences of schistosome hybridization

Timothy J. C. Anderson

NIH / KENYATTA UNIVERSITY RO1 SUBCONTRACT Characterization of drug resistance in field-collected schistosomes

Timothy J. C. Anderson

MEDICAL CBRN DEFENSE CONSORTIUM CONTRACT Well characterized aerosol NHP models for filovirus, arenavirus and alphavirus induced disease

Ricardo Carrion, Jr.

NIH / UNIVERSITY OF NEBRASKA–LINCOLN R21 SUBCONTRACT Structure-based design of peptide based entry inhibitors against Ebola virus infection

Ricardo Carrion, Jr.

NIH / WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION RO1 SUBCONTRACT Develop mRNA-platform vaccines

Christopher Chen

NIH / COLUMBIA UNIVERSITY RO1 SUBCONTRACT The epitranscriptome as a novel mechanism of arsenic-induced diabetes

Shelley A. Cole

5

RESEARCH GRANTS & CONTRACTS AWARDED IN 2021 SPONSOR, MECHANISM & TITLE

PRINCIPAL INVESTIGATOR

NIH / UNIVERSITY OF OKLAHOMA HEALTH SCIENCE CENTER SUBCONTRACT Strong Heart Study coordinating center

Shelley A. Cole

NIH / UNIVERSITY OF TEXAS AT SAN ANTONIO SUBCONTRACT Epigenetics of energy homeostasis, bioenergetics and obesity

Shelley A. Cole

NIH / UT HEALTH SAN ANTONIO SUBCONTRACT Development of marmoset age-dependent iPSC line resources to determine single cell transcriptome and regulome atlas

Marcel Daadi

ECONOMIC DEVELOPMENT AGENCY GRANT Texas Biomed nonhuman primate animal facility

Cory Hallam

NIH R21 Nanobody toolkit for human coronavirus classification

Andrew Hayhurst

NIH C06 Significant expansion of SNPRC’s specific pathogen free rhesus macaque colony for AIDS research

Deepak Kaushal

NIH SUPPLEMENT Increase Indian rhesus macaque colony at SNPRC for AIDS, COVID-19 and other infectious disease research

Deepak Kaushal

NIH SUPPLEMENT Improve and expand rhesus monkey housing in support of U42 HIV/AIDS activities

Deepak Kaushal

NIH SUPPLEMENT Baboon model of long term effects of SARS-CoV-2 infection

Deepak Kaushal

NIH / BAYLOR COLLEGE OF MEDICINE P30 SUBCONTRACT Texas Developmental Center for AIDS Research

Deepak Kaushal

NIH / ST. LOUIS UNIVERSITY RO1 SUBCONTRACT Role of gamma/delta T cells in vaccine induced immunity

Deepak Kaushal

NIH / TULANE UNIVERSITY RO1 SUBCONTRACT Host-directed therapy to augment anti-M.tb responses in the setting of HIV co-infection and to sterilize tuberculoma

Deepak Kaushal

NIH / UNIVERSITY OF CALIFORNIA, LOS ANGELES RO1 SUBCONTRACT Optimization and advanced proof-of-concept studies of a Listeria-vectored multi-antigenic vaccine against tuberculosis Deepak Kaushal NIH / WASHINGTON UNIVERSITY IN ST. LOUIS RO1 SUBCONTRACT Role of inducible bronchus associated lymphoid tissue in latent tuberculosis

Deepak Kaushal

NIH / WASHINGTON UNIVERSITY IN ST. LOUIS RO1 SUBCONTRACT A novel TH17-inducing mucosal vaccine for tuberculosis

Deepak Kaushal

NIH / WASHINGTON UNIVERSITY IN ST. LOUIS U19 SUBCONTRACT Targeting trained immunity and Th1/Th17 axis with combination adjuvants

Deepak Kaushal

NIH RO1 CNS myeloid cells as SIV reservoirs: persistent infection and rebound

Binhua (Julie) Ling

NIH / TULANE UNIVERSITY RO1 SUBCONTRACT Eradication of latent SIV from the CNS

Binhua (Julie) Ling

DEPARTMENT OF DEFENSE (DOD) GRANT Development of a live-attenuated vaccine platform against hemorrhagic-fever-causing arenaviruses

Luis Martinez-Sobrido

DOD / ABSS SOLUTIONS INC. SUBCONTRACT – Viral and microbial decontamination strategies for medical treatment facilities, close quarters and austere settings – Zeolites Project

Luis Martinez-Sobrido

DOD / UT HEALTH SAN ANTONIO SUBCONTRACT SARS-CoV-2 viral RNAs as unique biomarkers and therapeutic targets

Luis Martinez-Sobrido

DOD / UT HEALTH SCIENCE CENTER AT TYLER SUBCONTRACT Develop a novel drug candidate, CSP7, for treating COVID-19

Luis Martinez-Sobrido

6

SPONSOR, MECHANISM & TITLE

PRINCIPAL INVESTIGATOR

NIH CONTRACT Evaluating the efficacy of ROC-325 in a SARS-CoV-2 humanized ACE2-transgenic mouse model

Luis Martinez-Sobrido

NIH / ICAHN SCHOOL OF MEDICINE AT MT. SINAI SUBCONTRACT NIAID Centers of Excellence for Influenza Research and Response (CEIRR)

Luis Martinez-Sobrido

NIH / POP BIOTECHNOLOGIES R43 SUBCONTRACT Developing a thermostable SARS-CoV-2 RBD-particle vaccine

Luis Martinez-Sobrido

NIH / UNIVERSITY OF ALABAMA AT BIRMINGHAM RO1 SUBCONTRACT The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies

Luis Martinez-Sobrido

NIH / UT HEALTH SAN ANTONIO RO1 SUBCONTRACT Mechanism-based targeting of the RNA processing machinery of SARS-CoV-2

Luis Martinez-Sobrido

NIH / JOHNS HOPKINS UNIVERSITY RO1 SUBCONTRACT A STINGing vaccine for TB

Smriti Mehra

NIH / TULANE UNIVERSITY RO1 SUBCONTRACT Impact of tuberculosis on the development and function of the immune system in SIV-infected infants

Smriti Mehra

NIH / NEW YORK MEDICAL COLLEGE R21 SUBCONTRACT – Characterizing the physicochemical properties of membraneless condensates and its regulation by delta-9-tetrahydrocannabinol in HIV/SIV infection

Mahesh Mohan

NIH R56 Mapping the marmoset: characterizing the impacts of chimerism on marmoset development and aging

Corinna Ross

NIH / UT HEALTH SAN ANTONIO P30 SUBCONTRACT San Antonio Claude D. Pepper Older Americans Independence Center

Corinna Ross

NIH / UNIVERSITY OF TEXAS AT SAN ANTONIO U01 SUBCONTRACT Advancing brain health research through male germline editing in marmosets

Corinna Ross

NIH SUPPLEMENT Macrophage nuclear receptors, metabolism and immune effectors during health and M.tb infection – Diversity Supplement Larry Schlesinger NIH P51 Southwest National Primate Research Center

Larry Schlesinger

NIH KO1 Characterizing IL-22 driven chronic immune activation in HIV/TB co-pandemic

Riti Sharan

NIH R21 Tunneling nanotubes as an alternate route of Ebola virus dissemination

Olena Shtanko

NIH / FOX CHASE CHEMICAL DIVERSITY CENTER, INC. R42 SUBCONTRACT Development of small molecule therapeutics targeting hemorrhagic fever viruses

Olena Shtanko

NIH / UNIVERSITY OF PENNSYLVANIA R21 SUBCONTRACT Role of host angiomotin as a central regulator of filovirus egress and dissemination

Olena Shtanko

DOD / ABSS SOLUTIONS INC. SUBCONTRACT – Viral and microbial decontamination strategies for medical treatment facilities, close quarters and austere settings – CIMR Efficacy Project

Jordi B. Torrelles

FEDERAL SUBTOTAL: $97,232,177

TOTAL NEW GRANTS & CONTRACTS: $107,490,876

7

TEXAS BIOMEDICAL RESEARCH INSTITUTE P.O. BOX 760549 SAN ANTONIO, TEXAS 78245 www.txbiomed.org 210.258.9400